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Abstract: Epilepsy belongs to the most common and debilitating neurological disorders with
multifactorial pathophysiology and a high level of drug resistance. Therefore, with the aim of searching
for new, more effective, and/or safer therapeutics, we discovered a focused series of original hybrid
pyrrolidine-2,5-dione derivatives with potent anticonvulsant properties. We applied an optimized
coupling reaction yielding several hybrid compounds that showed broad-spectrum activity in widely
accepted animal seizure models, namely, the maximal electroshock (MES) test and the psychomotor
6 Hz (32 mA) seizure model in mice. The most potent anticonvulsant activity and favorable safety
profile was demonstrated for compound 30 (median effective dose (ED50) MES = 45.6 mg/kg,
ED50 6 Hz (32 mA) = 39.5 mg/kg, median toxic dose (TD50) (rotarod test) = 162.4 mg/kg).
Anticonvulsant drugs often show activity in pain models, and compound 30 was also proven
effective in the formalin test of tonic pain, the capsaicin-induced pain model, and the oxaliplatin
(OXPT)-induced neuropathic pain model in mice. Our studies showed that the most plausible
mechanism of action of 30 involves inhibition of calcium currents mediated by Cav1.2 (L-type) channels.
Importantly, 30 revealed high metabolic stability on human liver microsomes, negligible hepatotoxicity,
and relatively weak inhibition of CYP3A4, CYP2D6, and CYP2C9 isoforms of cytochrome P450,
compared to reference compounds. The promising in vivo activity profile and drug-like properties of
compound 30 make it an interesting candidate for further preclinical development.
Keywords: hybrid molecules; pyrrolidine-2,5-dione; anticonvulsant activity; antinociceptive activity;
in vitro binding/functional studies; absorption, distribution, metabolism, excretion, toxicity
(ADME-Tox) properties
1. Introduction
Epilepsy remains one of the least understood neurological diseases with complex and multifactorial
pathogenesis. It is estimated that about 50 million people worldwide suffer from this disease, making
it the second most common neurological disorder after stroke [1,2]. Despite unquestionable advances
in epilepsy research, nearly 30% of patients still experience uncontrolled, debilitating seizures [3].
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Furthermore, even if the desired therapeutic effect is achieved, most of the available antiepileptic
drugs (AEDs) often produce problematic side effects, e.g., memory impairment, diminished attention,
and executive function or somnolence, due to their unspecific inhibitory influence on the central
nervous system (CNS) [4]. In recent years, several new AEDs such as levetiracetam, brivaracetam,
lacosamide, or perampanel have been introduced into the pharmacotherapy of seizures. However,
despite their efficacy in several types of epilepsy, as well as better tolerance by patients, compared to
older AEDs, they have not resolved the problem of drug-resistant epilepsy [5].
The multitargeted compounds which usually show broad pharmacological activity seem to
be especially relevant for diseases with multifactorial origin and conditions with a high risk of
drug resistance, such as depression, cancer, Parkinson’s disease, Alzheimer’s disease, neuropathic
pain, and epilepsy [6–9]. Substances characterized by multitarget activity typically include hybrid
or chimeric structures that contain several pharmacophores merged as one chemical scaffold [10].
This “multistructural” chemical composition gives the possibility of interaction with different biological
targets potentially translating into better therapeutic efficacy. The most essential advantages of
multitargeted compounds vs. combination therapies, which are usually required in severe diseases,
include reduced risk of drug–drug interactions, limited side effects, and better patient compliance [11].
Our previous studies proved that the application of a molecular hybridization strategy may result
in anticonvulsants with a wide spectrum of activity in different animal models of epilepsy [9,12–15].
Impotently, a number of such molecules also displayed potent antinociceptive activity in the in vivo
studies. These compounds were designed as hybrid molecules on the basis of the pyrrolidine-2,5-dione
core ring that merges structural fragments of known and clinically used AEDs, namely, ethosuximide
(ETX), levetiracetam (LEV), and lacosamide (LCS). The in vivo data revealed that the several hybrid
substances showed distinctly more potent and/or wider anticonvulsant efficacy compared to each of
the aforementioned AEDs. In consequence, the hybrid compounds reported previously [9,12–15] were
active in all three seizure models, i.e., the maximal electroshock (MES), subcutaneous pentylenetetrazole
(scPTZ), and the psychomotor 6 Hz (32 mA) seizure model. In contrast, ETX protected mice only in the
scPTZ model, while LCS was active in the MES and 6 Hz seizure models; lastly, LEV showed efficacy
only in the 6 Hz seizure model. Thus, it is postulated that the proposed multifunctional compounds
may be potentially effective in a broad range of human epilepsies characterized by tonic–clonic
seizures, absence seizures, and importantly the most common focal seizures that affect more than 50%
patients [16].
The MES test is still recognized as one of the most useful experimental tools for early identification
of new AEDs, and it is recognized as an animal model of tonic–clonic seizures in human epilepsy [17].
The structure–activity relationship analysis of known AEDs that show potent protection in the MES
test revealed that the majority of these compounds contain two aromatic rings in their structure
(e.g., lamotrigine, phenytoin, or perampanel; see Figure 1). Therefore, we aimed to obtain new
hybrid compounds with increased protection in the MES test; we report herein a series of new
2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamides. These molecules were designed as analogues of
previously described 2-(2,5-dioxopyrrolidin-1-yl)-2-alkylacetamides with an additional benzene ring
attached to the side methyl group (marked in green, Figure 1). It should be stressed here that the
aforementioned 2-(2,5-dioxopyrrolidin-1-yl)-2-alkylacetamides displayed only weak activity in the
MES test [12,13]. Furthermore, we also hypothesized that the introduction of an additional aromatic
moiety resulting in an increased lipophilicity may afford better blood–brain barrier penetration
and more potent activity. As the amine function, we introduced unsubstituted phenylamine,
benzylamine, phenylethylamine, and phenylpropylamine or their selected derivatives containing
exclusively electron-withdrawing atoms or groups that appeared to be essential for anticonvulsant
activity on the basis of previous results [12,13]. The design process and the general structure of
the compounds described in the current paper are shown in Figure 1. For the selected most potent
anticonvulsant compounds, we also assessed their antinociceptive properties in vivo, as well as
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performed mechanism-of-action studies and characterized basic absorption, distribution, metabolism,
excretion, toxicity (ADME-Tox) properties in vitro.
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2.1. Chemistry
Compounds 3–31 were synthesized using a multistep procedure according to Scheme 1. First,
succinamic acid (1) was obtained by reacting equimolar amounts of commercially available succinic
anhydride with dl-phenylglycine, and this reaction was carried out in 70 ◦C in acetic acid. Succinamic
acid (1) was obtained as a solid substance after wash up with diethyl ether and was used without
future purification. Next, the hexa ethyldisilazane (H DS)-promoted cyclization reaction of 1,
performed in benzene according to previously reported method [18], yielded monocarboxylic acid (2).
The final compounds 3–31 were obtained by coupling of intermediate 2 ith respective primary
amine derivatives in the presence of carbonyldii idazole ( I) as the coupling reagent in dry
dimethylforma ide ( ) as a s l e t. is reacti as carrie t at r o te perature, and its
progress was monitored by high-perf r c li i c r t r ( ) (co pletion at ~24 h).
Final compounds were purified by flash column chromatography and were obtained as solid substances,
followed by c ncentration of organic solvents under r duced pressure. The target hybrid compoun s
were obtained with good yield (62.9–79.2%). The structures of intermediates a d final molecules were
confirmed by 1H-NMR, 13C-NMR (selected molecules), and/or LC–MS pectral analysis. Elemental
analyses (C, H, and N) w re performed for all the final c mpounds synthesized. The detailed
physicochemical and sp ctral data are summ rized in Section 3.
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In the case of compounds 24 and 30, the respective noncommercial primary amines A1 and A2
were synthesized prior to the coupling reaction. Amines A1 and A2 were obtained via reduction of
commercially available nitriles using the solid LiAlH4 as a reductive agent (Scheme S1, Supplementary
Materials). At first, the tetrahydrofuran (THF) solution of the given nitrile derivative was added
dropwise to the suspension of LiAlH4 in anhydrous THF at 0 ◦C. Afterward, the reaction mixture was
stirred at room temperature for additional 6 h. The progress of the reaction was monitored by HPLC.
After the reaction was completed, the excess of LiAlH4 was neutralized by addition of 10% NaOH
at 0 ◦C. Next, the reaction mixture was filtered through Celite 545 (Merck, Darmstadt, Germany),
and the obtained solution was extracted with dichloromethane (DCM). The organic layer was dried
over anhydrous Na2SO4, and then evaporated to dryness. Amines A1 and A2 were used to further
reactions without purification. The detailed synthetic procedure and the physicochemical and spectral
data for A1 and A2 are described in the Supplementary Materials.
2.2. Anticonvulsant Activity
Empirical screening in animal models of human epileptic seizures is still recognized as a standard
and effective paradigm in the discovery and development of new anticonvulsants [19]. Notably, this
approach enabled identification of nearly all commercially launched AEDs so far. It should also be
stressed that the screening approach enables detection of both substances acting on molecular targets
that are well known for existing anticonvulsants, as well as compounds with new and undefined modes
of action. In consequence, all final compounds 3–31 were initially evaluated in the MES test, which is
an experimental model of tonic–clonic epilepsy [17]. This test, as a mechanism-independent animal
seizure model, detects compounds capable of preventing the spread of seizures when all neurons in
the brain are maximally active. It is noteworthy that the MES test is still recognized as the most useful
preclinical seizure model and, hence, is widely employed during the early identification of new AED
candidates. Importantly, the MES test may also help to find substances with unique mechanism of
action [20].
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Bearing in mind the aforementioned facts, all final substances were initially studied in the
MES test after intraperitoneal (i.p.) administration at a fixed dose of 100 mg/kg in mice (in a group
consisting of four animals). The protection effect against MES seizures was observed at 0.5 h post
intraperitoneal (i.p.) injection. The pretreatment time was chosen on the basis of our previous
experimentations [9,12–15]. According to the screening data (Tables S1–S3, Supplementary Materials),
at least 50% protection, which was considered as satisfactory, was demonstrated for compounds 3, 4, 6,
8, 9 (anilinamide derivatives), 14, 19, 21, 22, 24 (benzylamide derivatives), 25, 27–30 (phenyletylamide
derivatives), and 31 (phenylpropanamide analogue). Notably, the maximal (100%) protection was
observed for 2-F (4), 3-CF3 (29), and 3-OCF3 (30) congeners. During the next step of pharmacological
characterization, all MES-active substances were tested in the mouse 6 Hz (32 mA), an animal model of
human focal seizures [21] (for details, see Tables S1–S3, Supplementary Materials). The data obtained
revealed that 12 molecules (3, 6, 14, 19, 22, 24, 25, 27–31) protected at least 50% of mice in this seizure
test. The full (100%) activity was observed only for 3-OCF3 benzylamide derivative 24, whereas 75%
efficacy was shown for 3, 25, and 27–30. According to the screening results, 11 compounds may be
considered as broad-spectrum anticonvulsants that are effective in both MES and 6 Hz (32 mA) seizure
models, i.e., 3, 6, 14, 19, 22, 24, 25, 27–31. In general, phenylethylamide derivatives 25 (H), 28 (4-Cl),
29 (3-CF3), and 30 (3-OCF3), and benzylamide derivative 24 (3-OCF3) displayed the most beneficial
anticonvulsant properties (i.e., the highest percentage of protection in each seizure model). A narrower
spectrum of protection was observed for anilinamides, which were effective predominantly in the
MES test (excluding 3 and 6). In parallel to the anticonvulsant screening, all the aforementioned active
compounds were studied in the rotarod test to assess their influence on motor coordination of mice.
In this assay, none of substances produced acute neurological toxicity at dose of 100 mg/kg (in some cases,
only minimal effects were seen). These results suggest a distinct separation between anticonvulsant
effective and toxic doses (i.e., inducing motor deficits), which was confirmed in the in vivo quantitative
investigations (for details, see Table 1). According to the aforementioned initial screening data, it may
be concluded that the most potent and broad anticonvulsant activity seemed to be provided by the
phenylethylamide derivatives. Taking into consideration the optimal substitution mode of the aromatic
ring, it can also be concluded that (1) the unsubstituted phenyl rings are preferential for activity in
each series, (2) the small substituents such as chlorine or fluorine atoms are preferential in the case
of anilinamide derivatives, and (3) chlorine atoms and large trifluoromethyl and trifluoromethoxy
groups seem to be more beneficial for activity among benzylamides and phenylethylamides.
In the next step of in vivo characterization, we determined the median effective doses (ED50) for
all anticonvulsants protecting 50% or more mice in each seizure model (MES or/and 6 Hz (32 mA)),
as well as the median toxic doses (TD50) in the rotarod test at the 0.5 h time point. Both the
aforementioned parameters enabled calculation of the protective indexes (PIs), which are a measure of
potential therapeutic window of the drug candidate. In parallel, we performed a series of comparative
studies using reference compounds, e.g., lacosamide (LCS), lamotrigine (LTG), and valproic acid (VPA),
which are active in the MES and 6 Hz (32 mA) seizure tests. The obtained results are summarized in
Table 1.
As expected on the basis of screening data, phenylethylamides 27, 29, and 30 displayed the most
potent activity in the MES and/or 6 Hz (32 mA) seizure tests. Satisfactory protection in the MES test
(50%) was shown for a benzylamide derivative 21 (this compound was unfortunately not effective in
the 6 Hz test). In general, more potent activity was observed in the 6 Hz (32 mA) seizure model, and the
lowest ED50 values were obtained with 6, 14, 22, 24, 27, 29, and 30. It should be emphasized that all
anilinamides (3, 4, 6, 8, 9) and benzylamides (14, 19, 21, 22, 24) did not impair motor coordination of
mice at doses as high as 300 mg/kg. Phenylethylamides 25, 28–30 displayed moderate acute neurological
toxicity (at doses around or below 200 mg/kg). Among the whole series of hybrid derivatives, the most
potent protection in both seizure models and moderate but acceptable acute neurological toxicity were
obtained with 30, which was identified as a lead compound. The comparison of data obtained with the
test compounds and reference AEDs (VPA in particular) indicated a more potent protection, as well
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as a predominantly more beneficial safety margin (expressed as PIs), for the majority of the hybrid
derivatives. It should be emphasized that VPA is still recognized as the most frequently prescribed
and the most effective first-line AED in different types of epilepsies [22]. However, potent activity in
both seizure models and beneficial PI values were observed for LCS and LTG, which act as sodium
channel blockers.
Table 1. The quantitative pharmacological parameters: median effective dose (ED50), median toxic
dose (TD50), and protective indexes (PIs) in mice intraperitoneally (i.p.) injected.
Compound TPE (h) a ED50 MES(mg/kg) b
ED50 6 Hz (32 mA)
(mg/kg) c
TD50 (rotarod)
(mg/kg) d PI (TD50/ED50)
e
3 0.5 >130 92.5 (72.3–118.3) >300 >3.2 (6 Hz)
4 0.5 73.2 (58.3–92.8) – >300 >4.1 (MES)
6 0.5 117.7 (92.6–149.6) 57.6 (33.9–97.9) >300 >2.5 (MES)
>5.2 (6 Hz)
8 0.5 73.5 (59.3–90.4) – >300 >4.1 (MES)
9 0.5 105.8 (100.3–111.6) – >300 >2.8 (MES)
14 0.5 >130 62.9 (45.7–86.7) >300 >4.7 (6 Hz)
19 0.5 90.7 (82.6–99.5) 89.9 (74.4–108.5) >300 >3.3 (MES)
>3.3 (6 Hz)
21 0.5 49.6 (44.3–55.7) – >300 >6.0 (6 Hz)
22 0.5 >130 57.6 (33.9–97.9) >300 >5.2 (6 Hz)
24 0.5 >130 43.8 (33.9–53.8) >300 >6.8 (6 Hz)
25 0.5 87.9 (82.0–94.3) 88.9 (83.3–94.9) 210.5(195.0–227.1)
2.4 (MES)
2.4 (6 Hz)
27 0.5 – 36.3 (24.9– 53.1) >300 8.3 (6 Hz)
28 0.5 117.4 (108.4–127.3) 88.1 (81.8–95.0) 272.5(253.2–293.3)
2.3 (MES)
2.9 (6 Hz)
29 0.5 55.4 (41.5–65.4) 49.3 (38.0–62.1) 178.8(164.1–188.5)
3.2 (MES)
3.6 (6 Hz)
30 0.5 45.6 (35.8–58.2) 39.5 (28.3–55.2) 162.4(144.0–183.1)
3.5 (MES)
4.1 (6 Hz)
31 0.5 – 103.8 (86.1–125.2) >300 2.9 (6 Hz)
LCS f 0.5 9.2 (8.5–10.0) 5.3 (3.5–7.8) 46.2 (44.5–48.0)
5.0 (MES)
8.8 (6 Hz)
LTG f 1.0 3.1 (1.9–4.7) 6.4 (4.1–9.9) 48.3 (37.4–62.6)
15.6 (MES)
7.5 (6 Hz)





Values in parentheses are 95% confidence intervals determined by probit analysis [23]. a Time to peak effect; b ED50
(MES, maximal electroshock seizure test); c ED50 (6 Hz psychomotor seizure test, 32 mA); d TD50 (acute neurological
toxicity determined in the rotarod test); e protective index (TD50/ED50); f reference antiepileptic drugs (AEDs):
lacosamide (LCS), lamotrigine (LTG), and valproic acid (VPA) tested in the same conditions. TPEs for model AEDs
taken from own experiments. A dash indicates not tested.
In summary, the proposed structural modification relying on the introduction of the additional
phenyl moiety in the acetamide linker did not increase activity in the MES test compared to aliphatic
analogues represented by maternal compounds DK-1 and AS-1 (see Figure 1), which was the main
hypothesis behind the current series of compounds. It should be stressed, however, that several
substances (e.g., 21, 24, 27, 29, and 30) revealed beneficial anticonvulsant activity, with an acceptable
safety profile; thus, they may be subjects for further structural optimization.
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2.3. Antinociceptive Activity
AEDs are also commonly used in the treatment of neuropathic pain and other central pain
conditions. Therefore, with an aim of further pharmacological characterization of compounds described
herein, we decided to study their antinociceptive properties in the in vivo assays. These studies were
performed for two representative molecules with different anticonvulsant profiles, namely, compound 4,
which showed protection exclusively in the MES test, and 30, which was active in both MES and 6 Hz
(32 mA) seizure models. At first, both aforementioned compounds were tested in the formalin-induced
tonic pain model, which is recognized as a valuable screening tool [24]. In this test, the injection
of formalin into the plantar surface of the mouse paw produces specific behaviors like paw lifting,
flinching, and licking. Furthermore, the nociceptive response is biphasic where, in phase I (0–5 min),
pain results from the direct activation of primary nociceptive afferents, and, in phase II (10–30 min),
pain results mainly from the central sensitization in the dorsal horn of the spinal cord [25]. Moreover,
it has been reported that formalin induces pathological changes that resemble those observed in nerve
injury and neuropathic pain [24]. Thus, this test has been successfully used to assess the analgesic
efficacy of a variety of compounds such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs),
corticosteroids, and N-methyl-d-aspartate (NMDA) receptor antagonists, as well as AEDs such as
carbamazepine, topiramate, or gabapentin [26,27].
As mentioned above, we investigated the analgesic properties of two of the most promising and
interesting compounds: 4 and 30. As shown in Figure 2, the i.p. administration of compound 4 prior
to the subcutaneous injection of formalin attenuated the nociceptive response in mice in both phases of
the test; however, in the first phase, the activity was statistically significant only at the highest dose of
120 mg/kg. It was slightly more efficient in the second phase of the model with an ED50 value equal to
98.9 mg/kg. In contrast, compound 30 was much more effective (almost four times more potent) in
both phases (phase I: ED50 = 21.5 mg/kg and phase II: ED50 = 24.8 mg/kg). Particularly interesting is
the activity of the compound in the first phase, since it suggests its efficacy with regard to the pain
associated with acute and direct damage/disfunction of the nerve endings. These results showed
favorable analgesic properties, especially for compound 30, which were subsequently confirmed in
other models of pain such as capsaicin-induced neurogenic pain and oxaliplatin (OXPT)-induced
neuropathic pain in mice.
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Figure 2. Antinociceptive activity of compounds 4 (A) and 30 (B) in the formalin test. Results are
shown as time of licking in phase I (0–5 min after intraplantar injection of formalin) and in phase II
(15–30 min after formalin injection). Each value represents the mean ± standard error of the mean (SEM)
for 8–10 animals. Statistical analysis: one-way ANOVA followed by post hoc Dunnett’s test. Statistical
significance compared to vehicle-treated animals (Tween): * p < 0.05, ** p < 0.01, **** p < 0.0001.
C—control group.
We used the capsaicin-induced model of pain to test the potential of the compounds to inhibit the
neurogenic (acute) response to noxious stimuli, which was suggested by their activity in the first phase
of the formalin test. Capsaicin activates C polymodal fibers and enhances their firing, which contributes
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to subsequent hyperalgesia. The molecular mechanism of action of capsaicin is the activation of the
nonselective cation channel, transient receptor potential vanilloid-1 (TRPV1), which is localized on
nociceptive free nerve endings. That induces the release of proinflammatory neuropeptides such as
calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and substance P (SP).
The phenomenon of the induction of tissue inflammation by the peripheral nervous system is called
neurogenic inflammation, and it is involved in the development of inflammatory and neuropathic
pain. AEDs such as gabapentin, topiramate, or lamotrigine decrease capsaicin-induced nocifensive
behavior [25]. We observed a similar effect especially in the case of compound 30, which significantly
attenuated the nociceptive response induced by capsaicin in a dose-dependent manner (Figure 3B).
Its ED50 value was found to be 35.3 mg/kg. Compound 4 was less active and was able to significantly
attenuate nociceptive response in capsaicin-induced pain by 37.9%, but only at the highest applied
dose of 120 mg/kg (Figure 3A). The obtained results show that the test compound 30 has the potential
for inhibiting acute, neurogenic pain, probably by stabilizing the firing polymodal fibers and/or central
mechanisms of analgesia.
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Figure 3. Antinociceptive activity of compounds 4 (A) and 30 (B) in the capsaicin test. Results are
shown as time of licking in the period of 5 min after intraplantar injection of capsaicin. Each value
represents the mean ± SEM for 8–10 animals. Statistical analysis: one-way ANOVA followed by post
hoc Dunnett’s test. Statistical significance compared to vehicle-treated animals (Tween): * p < 0.05,
*** p < 0.00, **** p < 0.0001. C—control group.
In order to investigate the analgesic activity of the most promising compound 30 in a neuropathic
pain model, we tested it in oxaliplatin (OXPT)-induced peripheral neuropathy, in which mechanical
and cold allodynia result from impaired function of ion channels, among others [28]. The early phase
of neuropathic pain appears hours after OXPT administration, while the late phase develops days
after OXPT. Thus, we tested compound 30 3 h and 7 days after the injection of OXPT. We investigated
the influence of compound 30 on tactile allodynia using the von Frey method. Three hours after the
administration of OXPT we observed a significant decrease in the mean value of force that caused
paw withdrawal reaction (1.89 ± 0.04 g) (64.2% of the baseline) compared to nontreated animals
(2.94 ± 0.06 g) (the baseline). Seven days after OXPT administration, the pain threshold was 2.00 ± 0.03
(68.0% of the baseline). The observed tactile allodynia was attenuated by compound 30, which elevated
pain sensitivity threshold in the early phase in a dose-dependent manner (Figure 4) (2.26 ± 0.08 g,
2.49 ± 0.05 g, and 2.97 ± 0.05 g at the dose of 20 mg/kg, 40 mg/kg, and 80 mg/kg, respectively,
which correspond to 76.8%, 84.7%, and 101.0% of the baseline value). In the late phase, the values
of pain threshold were as follows 2.18 ± 0.06 g, 2.60 ± 0.08 g, and 2.91 ± 0.05 g, which correspond
to 74.1%, 88.4%, and 98.9% of the baseline value. These results indicate that compound 30 has the
potential for relieving neuropathic pain.
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Figure 4. Antiallodynic effects of compound 30 administered at the doses of 20 mg/kg, 40 mg/kg,
and 80 mg/kg in the tactile allodynia evaluated in the von Frey test in the oxaliplatin (OXPT)-induced
model of peripheral neuropathy. Results compared to vehicle-treated group (pre 30). Statistical analysis:
repeated measures analysis of variance (ANOVA), followed by Dunnett’s post hoc comparison: * p < 0.05,
*** p < 0.001, **** p < 0.0001.
2.4. In Vitro Radioligand Binding Studies and Functional Assays
The previous studies in series of 2-(2,5-dioxopyrrolidin-1-yl)propanamides, represented by
compounds AS-1 and DK-1 (see Figure 1), showed that these molecules interact with voltage-gated
sodium channels and Cav1.2 (L-type) calcium channels at very high concentrations of 100 µM or
500 µM [12]. Taking into consideration the structural similarities of molecules described in the current
manuscript with their chemical prototypes AS-1 and DK-1, the binding studies toward aforementioned
molecular targets were performed commercially for several active substances from each subseries
(3, 4, 21, 24, 25, 27, 29, and 30). Furthermore, we also tested two other and well-known targets for
AEDs, namely, the Cav2.2 (N-type) calcium channel and gamma-aminobutyric acid (GABA)-A receptor.
With the aim of excluding potentially dangerous proarrhythmic properties for each compound, their
interaction with the potassium (hERG) channel was also tested. Notably, the potassium (hERG) channel
is recognized as one of the most important off-targets, and the potential effects on this ion channel
should be eliminated in early stages of the new drug development. The details are shown in Table 2.
The results of the binding studies showed that only four compounds 24, 27, 29, and 30 revealed
moderate binding to voltage-gated calcium channels Cav1.2 at a concentration of 10 µM. Importantly,
these substances were also identified as the most effective anticonvulsants with potent protection
especially in the 6 Hz (32 mA) seizure model. Thus, the interaction with Cav1.2 channels seems to be at
least partially responsible for activity in the aforementioned model of focal seizures. These observations
are consistent with results obtained in our previous studies that clearly indicate on Cav1.2 channel
antagonism as an important mechanism underlying anticonvulsant properties [13–15]. Notably,
it is well known that Cav1.2 channels are widely localized in the CNS neurons, predominantly on
post-synaptic parts; consequently, they regulate neuronal firing [29]. It should be emphasized that
the most current neurobiological studies implicate Cav1.2 channels in the pathogenesis of chronic
and neuropathic pain [30]. Thus, antagonists of these ion channels may be considered as promising
candidates for new antinociceptive drugs [31]. The functional assays applying the cell-based flux
studies performed for compounds 24, 27, 29, and 30 showed their moderate antagonist properties
(Table 3).
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Table 2. In vitro binding assays for several compounds at concentration of 10 µM or 100 µM.
% Inhibition of Control Specific Binding a
Assay
















(µM) 10 10 10 10 100
Compound
3 10.8 9.0 3.6 5.2 0.8
4 23.5 5.0 1.1 2.8 2.3
21 18.8 26.6 0.2 1.2 6.3
24 22.3 36.5 5.5 −0.8 4.4
25 14.8 19.0 2.5 3.6 4.8
27 20.1 38.3 3.8 0.7 2.7
29 18.3 44.2 −0.6 2.1 3.4
30 15.8 47.6 4.0 0.3 1.7
The data for the most potent compounds have been bolded for better visualization. a Results showing activity
higher than 50% are considered to represent a significant effect of the test compounds; results showing an inhibition
between 25% and 50% (bolded values) are indicative of a moderate effect; results showing an inhibition lower
than 25% are not considered significant. # Central nervous system (CNS) tetrodotoxin (TTX)-sensitive sodium
channels that include Nav1.1, Nav1.2, Nav1.3, and Nav1.6 subtypes. Binding studies were performed commercially
in Eurofins Cerep SA (Celle l’Evescault, France). Source: * rat cerebral cortex; ** human recombinant (HEK-293 cells).
Table 3. In vitro functional assays for several compounds at concentration of 10 µM.
Molecular Target % Inhibition of Control Agonist Response a







The data for the most potent compounds have been bolded for better visualization. a Results showing an inhibition
higher than 50% are considered to represent a significant effect of the test compounds; results showing an inhibition
between 25% and 50% (bolded values) are indicative of a moderate effect; results showing an inhibition lower than
25% are not considered significant. Functional studies were performed commercially in Eurofins Panlabs Discovery
Services Taiwan, Ltd. (New Taipei City, Taiwan).
Interestingly, none of the tested compounds interacted with voltage-gated sodium channels, Cav2.2
calcium channels, GABA-A receptors, and especially the potassium (hERG) channel at concentrations
as high as 100 µM. The latter result is particularly important since it minimizes the risk of potential
proarrhythmic activity of these compounds. Summing up, on the basis of the binding and functional
studies, it may be concluded that Cav1.2 channel antagonism is probably involved in the mechanism of
action for the compounds reported herein. Nevertheless, it should be stressed that the identification of
additional and currently undefined molecular targets responsible for the biological properties is highly
possible during further in vitro characterization.
2.5. In Vitro ADME-Tox Assays
Long-term use of AEDs may often lead to numerous adverse effects both acute (affecting the CNS
and the gastrointestinal tract) and chronic (including neuropsychiatric disorders or gastrointestinal
tract, endocrine, hematologic, liver, metabolic, dermatologic, and systemic symptoms) [32], as well as
drug–drug interactions (DDIs), especially with the metabolic origin mediated by different isoforms
of cytochrome P450 (CYP). Until now, 10 CYP isoforms have been identified in a typical human
liver, and six of them (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) appear to be
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engaged in biotransformation of most drugs. Notably, among these isoforms, CYP3A4, CYP2D6,
and CYP2C9 are responsible for the metabolism of more than 50% of marketed drugs and the associated
DDIs. The induction or inhibition of these P450 isotypes may influence the metabolic clearance and
blood concentration of co-administered drugs, resulting in lower therapeutic efficacy or toxic drug
effects, respectively. The problems related with the DDIs are especially visible for the first generation
of AEDs which may interact with different CYP isoforms. The clearest examples of these adverse
effects are phenytoin, phenobarbital, and carbamazepine which are known as CYP3A4, CYP2C9,
CYP1A2, and CYP2B6 inductors, and valproic acid, recognized as a CYP2C9 inhibitor. Notably,
the DDIs are described also for the newest AEDs, e.g., cannabidiol (CBD) and clobazam. Clobazam,
during the biotransformation, is N-demethylated by CYP3A4 and, to a lesser extent, by CYP2C19
and CYP2B. The main metabolite, N-desmethylclobazam (or norclobazam), is hydroxylated next
by CYP2C19. The DDI between CBD and clobazam leading to a significant increase in the level
of N-desmethylclobazam results from inhibition of CYP2C19 activity by CBD [33]. It should also
be stressed herein that some AEDs (including the newest preparations) form toxic metabolites
during biotransformation, e.g., the reactive metabolite of felbamate causing aplastic anemia [34]
or the 10,11-epoxide of carbamazepine, which facilitates its and the parent drug’s metabolism
(autoinduction) [35]. Consequently, the evaluation of CYPs induction/inhibition or hepatotoxic
potential of new biologically active compounds is crucial at an earlier stage of drug development.
Considering the aforementioned facts, drug-like properties of the most promising compounds
from each subseries (4, 24, 30) were estimated next within this study. Standard in vitro methods were
used for ADME-Tox parameter evaluation. All tests were performed acording to descrived previously
protocols [14,15,36].
2.5.1. Parallel Artificial Membrane Permeability Assay (PAMPA)
Passive diffusion was tested in the parallel artificial membrane permeability assay (PAMPA)
and expressed as the permeability coefficient (Pe). A highly permeable compound, caffeine (CFN),
and a poorly permeable compound, norfloxacin (NFX), were used as the references. All compounds
selected for this assay (4, 24 and 30) showed very high ability to passively diffuse through the biological
membranes with Pe values close to or even higher (compound 30) than CFN (Table 4).
Table 4. The results obtained in parallel artificial membrane permeability assay (PAMPA), expressed as
the permeability coefficient (Pe).
Compound Pe (10−6 cm/s) ± SD a
CFN b 12.22 ± 0.9
NFX c 0.056 ± 0.0
4 11.25 ± 0.7
24 10.87 ± 0.5
30 13.20 ± 1.5
a Tested in triplicate; b caffeine (CFN); c norfloxacin (NFX).
2.5.2. Metabolic Stability
Human liver microsomes (HLMs) were used for metabolic stability determination. Moreover,
the most probable phase I reactions and structures of metabolites were proposed according to ion
fragment analyses with the in silico support of MetaSite 6.0.1 software. In general, pyrrolidine-2,5-dione
derivatives displayed satisfied stability as their conversion into metabolites was lower than 30% during
120 min incubation with HLMs. These results correlate with our previous studies, where high
metabolic stability within this chemical group was also found [9,12,14,15,37]. Compound 4 showed
the highest susceptibility for enzymatic biotransformations (71.4% of parent compound remained in
the reaction mixture; see Figure S1, Supplementary Materials), resulting in double-hydroxylations
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(M1), pyrrolidine-2,5-dione ring hydrolysis (M2), or monohydroxylation (M3) as the most probable
metabolic pathways (Figures S2 and S7, Supplementary Materials). On the other hand, an excellent
metabolic stability of compound 24 was observed. Less than 4% of this derivative was converted
into double-hydroxylated metabolite M1 (Figures S3, S4, and S7, Supplementary Materials). Finally,
two monohydroxylated metabolites (M1, M2) were found in the reaction mixture with HLMs and 30,
and around 17% of this compound was metabolized (Figures S5–S7, Supplementary Materials).
2.5.3. Influence on Function of Cytochrome P450 Isoforms—CYP3A4, CYP2D6, and CYP2C9
The luminescent CYP3A4, 2D6, and 2C9 P450-Glo assays were used for the prediction of DDIs
risk. In case of CYP3A4, all tested derivatives statistically significantly inhibited its activity at 10 µM.
The highest inhibition was observed for derivatives with trifluoromethoxy substituent 24 and 30.
These compounds still slightly inhibited CYP3A4 activity (p < 0.05) even at low concentration (1 µM).
However, this effect was much weaker than that observed for 1 µM of the reference CYP3A4 inhibitor
ketoconazole (KE) (Figure 5)
Furthermore, slight but statistically significant activation of CYP2D6 was observed for all
compounds, whereas quinidine (QD) used here as the reference inhibited this isoform entirely at 1 µM
(Figure 6).
Surprisingly, the opposite effect on CYP2C9 was observed within this group, whereby compounds
4 and 30 blocked its activity at the highest concentrations of 10 and 25 µM, whereas the same doses of
24 activated this CYP isoform up to 140% of control. However, the observed inhibition effect of 4 and
30 was found to be weaker in comparison to the reference inhibitor sulfaphenazole (SE), which almost
completely blocked CYP2C9 activity at 1 µM (Figure 7).
2.5.4. Determination of Hepatotoxicity Risk
The hepatotoxicity assessment was done with use of hepatoma HepG2 cells, which were incubated
for 72 h in the presence of 1–100 µM concentrations of 4, 24, and 30. The CellTiter 96® aqueous
nonradioactive cell proliferation assay (MTS) purchased from Promega (Madison, WI, USA) was
used for determination of cell viability. The absorbance was measured using a microplate reader
EnSpire (PerkinElmer, Waltham, MA, USA) at 492 nm. The obtained results confirmed the safety of the
investigated series. The statistically significant (p < 0.001) effect on cells viability was determined for
compound 30, but only at the very high concentration of 100 µM (Figure 8).
Overall, the results obtained in the in vitro ADME-Tox assays indicate satisfactory drug-like
properties of all tested compounds (4, 24, and 30). In particular, very high (similar to CFN) passive
diffusion in PAMPA, excellent metabolic stability, and low hepatotoxic effects were confimed. In general,
DDI assays showed potential interactions of tested derivatives with all CYP isoforms used. However,
the observed effects were much weaker than when using the reference inhibitors KE, QD, and SE.
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by Bonferroni’s comparison test (*** p < 0.001, **** p < 0.0001) compared with negative control dimethyl sulfoxide (DMSO) 1% in growth medium).
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3. Materials and Methods
3.1. Chemistry
All chemicals and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and
were used without further purification. Melting points (m.p.) were determined in open capillaries
on a Büchi 353 melting point apparatus (Büchi Labortechnik, Flawil, Switzerland). Thin-layer
chromatography (TLC) and gradient UPLC chromatography were used to assess the purity and
homogeneity of the compounds. TLC was carried out on silica gel 60 F254 pre-coated aluminum sheets
(Macherey-Nagel, Düren, Germany), using the following developing systems: S1–DCM:MeOH (9:0.3;
v/v), S2–DCM:MeOH (9:0.5; v/v), S3–DCM:MeOH (9:0.7; v/v), S4–DCM:MeOH (9:1; v/v). Spot detection
was carried out using ultraviolet (UV) light (λ = 254 nm). The UPLC and mass spectra (LC–MS)
were obtained on a Waters ACQUITY™ TQD system (Waters, Milford, CT, USA) with the MS-TQ
detector and UV–Vis–DAD eλ detector. The ACQUITY UPLC BEH C18, 1.7 µm (2.1 × 100 mm)
column was used with the VanGuard Acquity UPLC BEH C18, 1.7 µm (2.1 × 5 mm) (Waters, Milford,
CT, USA). Standard solutions (1 mg/mL) of each compound were prepared in an analytical grade
MeCN/water mixture (1:1; v/v). Conditions applied were as follows: eluent A (water/0.1% HCOOH),
eluent B (MeCN/0.1% HCOOH), a flow rate of 0.3 mL/min, a gradient of 5–100% B over 10 min,
and an injection volume of 10 µL. The UPLC retention times (tR) are given in minutes. The purity
of target compounds determined by use of chromatographic UPLC method was ≥95%. Preparative
column chromatography was performed using silica gel 60 (particle size 0.063–0.200; 70–230 Mesh
ATM) purchased from Macherey-Nagel (Duren, Germany). Elemental analyses (C, H, and N) for final
compounds were carried out by a micro method using the elemental Vario EI III Elemental analyzer
(Hanau, Germany). The results of elemental analyses were within ±0.4% of the theoretical values.
1H-NMR and 13C-NMR spectra were obtained in CDCl3 or dimethyl sulfoxide (DMSO)-D6 in a Varian
Mercury spectrometer (Varian Inc., Palo Alto, CA, USA), in DMSO-D6 operating at 300 MHz (1H-NMR)
and 75 MHz (13C-NMR), or in a JEOL-500 spectrometer (JEOL USA, Inc. MA, USA), in CDCl3 operating
at 500 MHz (1H-NMR) and 126 MHz (13C-NMR). Chemical shifts are reported in δ values (ppm)
relative to tetramethylsilane (TMS) δ = 0 (1H), as an internal standard. The J values are expressed in
Hertz (Hz). Signal multiplicities are represented by the following abbreviations: s (singlet), br. s (broad
singlet), d (doublet), dd (doublet of doublet), dq (doublet of quartets), t (triplet), td (triplet of doublets),
q (quartet), and m (multiplet).
3.1.1. Synthetic Procedure for Succinamic Acid (1)
Succinic anhydride (5.0 g, 50 mmol, 1 equivalent (eq)) was dissolved in 50 mL of glacial acetic acid
and, afterward, an equimolar amount of dl-phenylglycine (7.56 g) was added. The reaction mixture
was heated at 70 ◦C and next stirred for 12 h. After this time, acetic acid was evaporated to dryness.
The intermediate 1 was obtained as a solid substance after wash up with diethyl ether.
4-((Carboxy(phenyl)methyl)amino)-4-oxobutanoic Acid (1)
White solid. Yield: 92% (11.54 g); m.p. 199.4–200.6 ◦C; TLC: Rf = 0.25 (S4); UPLC (purity 100%):
tR = 2.77 min. LC–MS (ESI): m/z calculated for C12H13NO5 (M + H)+ 252.08, found 252.1.
3.1.2. Synthetic Procedure for Monocarboxylic Acid (2)
To a suspension of the appropriate succinamic acid 1 (45 mmol, 1 eq) in dry benzene (150 mL),
ZnCl2 (6.13 g, 45 mmol, 1 eq) was added, and the mixture was heated to 80 ◦C. Next, a solution of
HMDS (10.89 g, 14.14 mL, 67.5 mmol, 1.5 eq) in dry benzene (15 mL) was added dropwise over 30 min.
The reaction mixture was refluxed for an additional 12 h and concentrated under reduced pressure.
After concentration, the residual solid was dissolved in DCM and extracted with 0.1 M HCl (3 × 50 mL),
water (3 × 50 mL), and saturated brine (3 × 50 mL). The organic layer was dried over anhydrous
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Na2SO4 and then evaporated to dryness. Intermediate 2 was obtained as a solid substance after wash
up with diethyl ether.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenylacetic Acid (2)
White solid. Yield: 91% (9.54 g); m.p. 198.3–199.7 ◦C; TLC: Rf = 0.46 (S4); UPLC (purity 100%):
tR = 3.41 min. LC–MS (ESI): m/z calculated for C12H11NO4 (M + H)+ 234.08, found 234.1. 1H-NMR
(300 MHz, DMSO-D6) δ 2.73 (s, 4H, imide), 5.76 (s, 1H, CH-COOH), 7.26–7.35 (m, 3H, ArH) 7.36–7.45
(m, 2H, ArH), 13.22 (br. s, 1H, COOH).
3.1.3. Synthetic Procedure for Target Compounds (3–31)
Carbonyldiimidazole (0.585 g, 3.6 mmol, 1.2 eq) was dissolved in 10 mL of anhydrous DMF.
Afterward, the solution was added to intermediate 2 (3 mmol, 1 eq) dissolved in 10 mL of anhydrous
DMF (while stirring). After 0.5 h, the appropriate amine (3 mmol, 1 eq) dissolved in 5 mL of anhydrous
DMF was added dropwise. The mixture was stirred for approximately 24 h at room temperature and
evaporated to dryness. Column chromatography was applied for purification of crude products, using
the following developing systems: S1 (3–20), S2 (21–31). The desired compounds were obtained as
solid substances followed by concentration of organic solvents under reduced pressure.
2-(2,5-Dioxopyrrolidin-1-yl)-N,2-diphenylacetamide (3)
White solid, yield: 69.4%, (0.63 g); m.p. 155.8–156.3 ◦C; TLC: Rf = 0.52 (S1); UPLC (purity >99.9%):
tR = 5.46 min. LC–MS (ESI): m/z calculated for C18H16N2O3 (M + H)+ 309.12, found 309.2.
1H-NMR (300 MHz, CDCl3) δ 2.74 (s, 4H, imide), 5.90 (s, 1H, CH), 7.11 (d, J = 7.3 Hz, 1H, ArH),
7.24–7.30 (m, 2H, ArH), 7.36–7.46 (m, 5H, ArH), 7.52 (s, 1H, NH), 7.58–7.67 (m, 2H, ArH). 13C-NMR
(75 MHz, CDCl3) δ 28.2, 59.2, 120.1, 124.9, 129.0, 129.5, 129.6, 129.9, 133.8, 137.0, 164.8, 176.6. Analysis
calculated for C18H16N2O3 (308.34): C: 70.12, H: 5.23, N: 9.09; found C: 70.25, H: 5.37, N: 9.26.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(2-fluorophenyl)-2-phenylacetamide (4)
White solid, yield: 68.7%; (0.67 g) m.p. 106.6–107.1 ◦C; TLC: Rf = 0.51 (S1); UPLC (purity >99.9%):
tR = 5.52 min. LC–MS (ESI): m/z calculated for C18H15FN2O3 (M + H)+ 327.11, found 327.3. 1H-NMR
(300 MHz, CDCl3) δ 2.78 (s, 4H, imide), 5.92 (s, 1H, CH), 6.98–7.11 (m, 3H, ArH), 7.42–7.47 (m, 3H, ArH),
7.62–7.68 (m, 3H, ArH, NH), 8.25 (td, J = 7.91, 1.76 Hz, 1H, ArH). 13C-NMR (75 MHz, CDCl3) δ 28.2,
59.3, 114.8 (d, J = 18.4 Hz), 121.7, 124.5, 125.0, 125.1, 125.6 (d, J = 10.4 Hz), 129.6, 129.7–129.9, 133.6, 152.5
(d, J = 243.0 Hz), 154.1–154.1, 164.7, 176.4. Analysis calculated for C18H15FN2O3 (326.33): C: 66.25,
H: 4.63, N: 8.58; found C: 66.32, H: 4.71, N: 8.79.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(3-fluorophenyl)-2-phenylacetamide (5)
White solid, yield: 72.3%, (0.71 g); m.p. 148.2–149.1 ◦C; TLC: Rf = 0.55 (S1); UPLC (purity >99.9%):
tR = 5.81 min. LC–MS (ESI): m/z calculated for C18H15FN2O3 (M + H)+ 327.11, found 327.4. 1H-NMR
(300 MHz, CDCl3) δ 2.75 (s, 4H, imide), 5.89 (s, 1H, CH), 6.75–6.83 (m, 1H, ArH), 6.96–7.00 (m, 1H, ArH),
7.20 (td, J = 8.2, 6.5 Hz, 1H, ArH), 7.35–7.45 (m, 4H, ArH), 7.57–7.62 (m, 3H, ArH, NH). 13C-NMR
(75 MHz, CDCl3) δ 28.2, 59.2, 107.6 (d, J = 26.5 Hz) 111.6 (d, J = 21.9 Hz) 115.3 (d, J = 3.5 Hz) 129.6, 129.7,
129.8, 130.0, 130.1, 133.6, 162.7 (d, J = 246.5 Hz) 164.9, 176.5. Analysis calculated for C18H15FN2O3
(326.33): C: 66.25, H: 4.63, N: 8.58; found C: 66.09, H: 4.39, N: 8.42.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(4-fluorophenyl)-2-phenylacetamide (6)
White solid, yield: 70.6%, (0.69 g); m.p. 143.4–143.9 ◦C; TLC: Rf = 0.48 (S1); UPLC (purity >99.9%):
tR = 5.59 min. LC–MS (ESI): m/z calculated for C18H15FN2O3 (M + H)+ 327.11, found 327.4. 1H-NMR
(300 MHz, CDCl3) δ 2.75 (s, 4H, imide), 5.88 (s, 1H, CH), 6.92–6.99 (m, 2H, ArH), 7.30–7.38 (m, 2H,
ArH), 7.40–7.46 (m, 3H, ArH), 7.48 (br. s, 1H, NH), 7.56–7.64 (m, 2H, ArH). 13C-NMR (75 MHz, CDCl3)
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δ 28.2, 59.1, 114.9–116.3, 122.1 (d, J = 8.1 Hz), 129.5, 129.7, 129.8, 133.0 (d, J = 3.5 Hz), 133.8, 159.6 (d,
J = 244.2 Hz) 164.8, 176.6. Analysis calculated for C18H15FN2O3 (326.33): C: 66.25, H: 4.63, N: 8.58;
found C: 66.31, H: 4.47, N: 8.62.
N-(2-Chlorophenyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (7)
White solid, yield: 64.3%, (0.65 g); m.p. 76.8–78.6 ◦C; TLC: Rf = 0.56 (S1); UPLC (purity >99.9%):
tR = 6.19 min. LC–MS (ESI): m/z calculated for C18H15ClN2O3 (M + H)+ 343.08, found 343.8. 1H-NMR
(300 MHz, CDCl3) δ 2.79 (s, 4H, imide), 5.90 (s, 1H, CH), 7.01 (td, J = 7.7, 1.4 Hz, 1H, ArH),
7.20–7.28 (m, 2H, ArH), 7.42–7.50 (m, 3H, ArH), 7.65–7.70 (m, 2H, ArH), 7.92 (br. s, 1H, NH), 8.34 (dd,
J = 7.9, 1.4 Hz, 1H, ArH). 13C-NMR (75 MHz, CDCl3) δ 25.3, 28.3, 59.4, 121.2, 123.0, 125.2, 127.7, 128.9,
129.6, 129.8, 130.0, 133.6, 134.0, 164.8, 176.4. Analysis calculated for C18H15ClN2O3 (342.78): C: 63.07,
H: 4.41, N: 8.17; found C: 63.31, H: 4.22, N: 8.25.
N-(3-Chlorophenyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (8)
White solid, yield: 72.8%, (0.75 g); m.p. 109.4–109.9 ◦C; TLC: Rf = 0.49 (S1); UPLC (purity >99.9%):
tR = 6.26 min. LC–MS (ESI): m/z calculated for C18H15ClN2O3 (M + H)+ 343.08, found 343.8. 1H-NMR
(300 MHz, CDCl3) δ 2.77 (s, 4H, imide), 5.89 (s, 1H, CH), 7.05–7.16 (m, 1H, ArH), 7.18–7.24 (m, 2H, ArH),
7.41–7.46 (m, 3H, ArH), 7.50–7.54 (m, 2H, NH, ArH), 7.57–7.62 (m, 2H, ArH). 13C-NMR (75 MHz,
CDCl3) δ 28.2, 59.2, 118.1, 120.2, 125.0, 129.6, 129.8, 129.9, 133.5, 134.6, 138.1, 164.9, 176.5. Analysis
calculated for C18H15ClN2O3 (342.78): C: 63.07, H: 4.41, N: 8.17; found C: 63.01, H: 4.69, N: 8.24.
N-(4-Chlorophenyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (9)
White solid, yield: 69.6%, (0.72 g); m.p. 103.8–105.6 ◦C; TLC: Rf = 0.54 (S1); UPLC (purity >99.9%):
tR = 6.16 min. LC–MS (ESI): m/z calculated for C18H15ClN2O3 (M + H)+ 343.08, found 343.8. 1H-NMR
(300 MHz, CDCl3) δ 2.76 (s, 4H, imide), 5.88 (s, 1H, CH), 7.20–7.24 (m, 1H, ArH), 7.25–7.35 (m, 3H, ArH),
7.40–7.45 (m, 3H, ArH), 7.52 (s, 1H, NH), 7.57–7.62 (m, 2H, ArH). 13C-NMR (75 MHz, CDCl3) δ 15.3,
28.2, 59.2, 65.8, 121.4, 129.0, 129.6, 129.7, 129.8, 130.0, 133.7, 135.6, 164.8, 176.5. Analysis calculated for
C18H15ClN2O3 (342.78): C: 63.07, H: 4.41, N: 8.17; found C: 63.31, H: 4.34, N: 8.37.
(2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(2-(trifluoromethyl)phenyl)acetamide) (10)
White solid, yield: 71.1%, (0.80 g); m.p. 162.2–163.4 ◦C; TLC: Rf = 0.58 (S1); UPLC (purity > 99.9%):
tR = 6.59 min. LC–MS (ESI): m/z calculated for C19H15F3N2O3 (M + H)+ 377.10, found 377.5. 1H-NMR
(300 MHz, CDCl3) δ 2.79 (s, 4H, imide), 5.98 (s, 1H, CH), 7.32–7.38 (m, 3H, ArH), 7.42–7.49 (m, 4H, ArH),
7.51–7.62 (m, 2H, ArH), 7.78 (s, 1H, NH). 13C-NMR (75 MHz, CDCl3) δ 27.8, 59.4, 116.2 (d, J = 271.8 Hz),
118.3, 124.7 (q, J = 32.3 Hz), 126.3 (q, J = 4.2 Hz) 128.2, 128.9, 129.4, 132.1, 140.3, 163.2, 177.4. Analysis
calculated for C19H15F3N2O3 (376.34): C: 60.64, H: 4.02, N: 7.44; found C: 60.44, H: 4.42, N: 7.28.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethyl)phenyl)acetamide (11)
White solid, yield: 68.9%, (0.78 g); m.p. 158.2–159.4 ◦C; TLC: Rf = 0.60 (S1); UPLC (purity >99.9%):
tR = 6.52 min. LC–MS (ESI): m/z calculated for C19H15F3N2O3 (M + H)+ 377.10, found 377.5. 1H-NMR
(300 MHz, CDCl3) δ 2.77 (s, 4H, imide), 5.92 (s, 1H, CH), 7.38 (d, J = 10.3 Hz, 1H, ArH), 7.37 (s, 1H, ArH),
7.41–7.47 (m, 3H, ArH), 7.55–7.66 (m, 4H, ArH), 7.70 (s, 1H, NH) 13C-NMR (75 MHz, CDCl3) δ 28.2,
59.2, 116.8, 116.8–116.9, 121.5 (q, J = 3.5 Hz), 123.7 (d, J = 272.9 Hz), 123.2, 129.5, 129.6, 129.8, 129.8,
131.4 (q, J = 33.0 Hz), 133.5, 137.5, 165.1, 176.5. Analysis calculated for C19H15F3N2O3 (376.34): C: 60.64,
H: 4.02, N: 7.44; found C: 60.51, H: 4.27, N: 7.31.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(4-(trifluoromethyl)phenyl)acetamide (12)
White solid, yield: 73.1%, (0.82 g); m.p. 188.1–188.5 ◦C; TLC: Rf = 0.58 (S1); UPLC (purity >99.9%):
tR = 6.59 min. LC–MS (ESI): m/z calculated for C19H15F3N2O3 (M + H)+ 377.10, found 377.5. 1H-NMR
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(300 MHz, CDCl3) δ 2.77 (s, 4H, imide), 5.92 (s, 1H, CH), 7.42–7.47 (m, 3H, ArH), 7.48–7.53 (m, 4H, ArH),
7.58–7.63 (m, 2H, ArH), 7.69 (s, 1H, NH). 13C-NMR (75 MHz, CDCl3) δ 28.2, 59.2, 118.5 (d, J = 271.8 Hz),
119.7, 126.1 (q, J = 32.3 Hz), 126.2 (q, J = 4.2 Hz) 129.6, 129.7, 129.8, 133.5, 140.0, 165.1, 176.5. Analysis
calculated for C19H15F3N2O3 (376.34): C: 60.64, H: 4.02, N: 7.44; found C: 60.52, H: 4.34, N: 7.31.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethoxy)phenyl)acetamide (13)
White solid, yield: 68.7%, (0.79 g); m.p. 132.6–133.4 ◦C; TLC: Rf = 0.66 (S2); UPLC (purity >99.9%):
tR = 6.76 min. LC–MS (ESI): m/z calculated for C19H15F3N2O4 (M + H)+ 393.10, found 393.2. 1H-NMR
(500 MHz, CDCl3) δ 2.77 (s, 4H, imide), 5.88 (s, 1H, CH), 5.98 (br. s, 1H, NH), 7.09–7.12 (m, 2H, ArH),
7.18 (d, J = 8.0 Hz, 1H, ArH), 7.33–7.43 (m, 4H, ArH), 7.59–7.62 (m, 2H, ArH). 13C-NMR (126 MHz,
CDCl3) δ 27.5, 56.2, 118.2, 120.2, 120.8 (q, J = 257.1 Hz), 124.3, 127.2, 128.8, 129.9, 130.8, 132.4, 141.7,
147.2, 166.2, 175.7. Analysis calculated for C19H15F3N2O4 (392.33): C: 58.17, H: 3.85, N: 7.14, found C:
58.43, H: 3.98, N: 7.03.
N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (14)
White solid, yield: 71.2%, (0.69 g); m.p. 128.3–129.9 ◦C; TLC: Rf = 0.45 (S1); UPLC (purity >99%):
tR = 5.24 min. LC–MS (ESI): m/z calculated for C19H18N2O3 (M + H)+ 323.13, found 323.3. 1H-NMR
(300 MHz, CDCl3): δ 2.77 (s, 4H, imide), 4.35–4.44 (m, 1H, CH2), 4.51–4.61 (m, 1H, CH2), 5.77(s, 1H, CH),
5.96 (br. s, 1H, NH), 7.22–7.40 (m, 5H, ArH), 7.54–7.64 (m, 5H, ArH). 13C-NMR (75 MHz, CDCl3):
δ 28.2, 43.9, 58.5, 76.8, 77.5, 127.1, 127.5, 128.4, 130.3, 134.1, 137.6, 166.5, 176.4. Analysis calculated for
C19H18N2O3 (322.36): C: 70.79, H: 5.63, N: 8.69; found C: 70.89, H: 5.61, N: 8.72.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(2-fluorobenzyl)-2-phenylacetamide (15)
White solid, yield: 74.5%, (0.76 g); mp. 148.3–149.3 ◦C; TLC: Rf = 0.55 (S1); UPLC
(purity >99,9%): tR = 5.36 min. LC–MS (ESI): m/z calculated for C19H17N2O3F (M + H)+ 341.12,
found 341.13. 1H-NMR (300 MHz, CDCl3): δ 2.75 (s, 4H, imide), 4.50 (dd, J = 5.7, 4.1 Hz,
2H, CH2), 5.74 (s, 1H, CH), 6.02 (br. s, 1H, NH), 6.94–7.03 (m, 1H, ArH), 7.07–7.15 (m, 1H, ArH),
7.19–7.28 (m, 1H, ArH), 7.33–7.41 (m, 4H, ArH), 7.54–7.59 (m, 2H, ArH). 13C-NMR (75 MHz, CDCl3):
δ 28.2, 38.0 (d, J = 4.6 Hz), 58.5, 115.1, 115.4, 124.3, 124.5, 124.7, 129.3 (d, J = 8.1 Hz), 129.4, 129.5, 129.9,
134.1, 160.7 (dd, J = 249.9, 1.0 Hz), 166.7, 176.5. Analysis calculated for C19H17N2O3F (340.35): C: 67.05,
H: 5.03, N: 5.58; found C: 67.01, H: 5.36, N: 5.29.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(3-fluorobenzyl)-2-phenylacetamide (16)
White solid, yield: 69.4%, (0.71 g); m.p. 136.7–137.7 ◦C; TLC: Rf = 0.49 (S1); UPLC (purity >99.9%):
tR = 5.40 min. LC–MS (ESI): m/z calculated for C19H17N2O3F (M + H)+ 341.12, found 341.3. 1H-NMR
(300 MHz, CDCl3): δ 2.77 (s, 4H, imide) 4.52 (dd, J = 15.4, 5.6 Hz, 2H, CH2), 5.76 (s, 1H, CH),
5.98 (br. s, 1H, NH), 6.90–7.05 (m, 3H, ArH), 7.23–7.32 (m, 1H, ArH), 7.35–7.42 (m, 3H, ArH),
7.56–7.61 (m, 2H, ArH). 13C-NMR (75 MHz, CDCl3): δ 28.2, 43.4, 58.5, 114.3 (d, J = 23.0 Hz), 114.4 (d,
J = 20.7 Hz), 122.8, 129.7 (d, J = 28.8 Hz), 129.5, 130.2 (d, J = 9.2 Hz), 134.1, 140.3 (d, J = 6.9 Hz), 163.0 (d,
J = 246.5 Hz), 166.8, 176.5. Analysis calculated for C19H17N2O3F (340.35): C: 67.05, H: 5.03, N: 5.58;
found C: 67.19, H: 5.22, N: 5.66.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(4-fluorobenzyl)-2-phenylacetamide (17)
White solid, yield: 65.7%, (0.67 g); mp. 146.3–147.7 ◦C; TLC: Rf = 0.45 (S1); UPLC (purity >99.9%):
tR = 5.39 min. LC–MS (ESI): m/z calculated for C19H17N2O3F (M + H)+ 341.12, found 341.1. 1H-NMR
(300 MHz, CDCl3): δ 2.76 (s, 4H, imide), 4.31 (dd, J = 15.0, 5.5 Hz, 2H, CH2), 5.75 (s, 1H, CH),
5.95 (br. s, 1H, NH), 6.95–7.03 (m, 2H, ArH), 7.18–7.27 (m, 2H, ArH), 7.34–7.40 (m, 3H, ArH),
7.52–7.59 (m, 2H, ArH). 13C-NMR (75 MHz, CDCl3): δ 28.2, 43.2, 58.5, 115.5 (d, J = 21.9 Hz), 129.1 (d,
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J = 8.1 Hz), 129.4, 129.9, 133.5 (d, J = 3.5 Hz), 134.2, 162.1 (d, J = 246.5 Hz), 166.6, 176.5. Analysis
calculated for C19H17N2O3F (340.35): C: 67.05, H: 5.03, N: 5.58; found C: 67.18, H: 5.29, N: 5.41.
N-(2-Chlorobenzyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (18)
White solid, yield: 66.3%, (0.71 g); m.p. 152.0–153.6 ◦C; TLC: Rf = 0.55 (S1); UPLC (purity 97%):
tR = 5.79 min. LC–MS (ESI): m/z calculated for C19H17N2O3Cl (M + H)+ 357.09, found 357.1. 1H-NMR
(300 MHz, CDCl3): δ 2.75 (s, 4H, imide), 4.53 (dd, J = 6.1, 2.4 Hz, 2H, CH2), 5.74 (s, 1H, CH), 6.11 (br. s, 1H,
NH), 7.16–7.28 (m, 2H, ArH), 7.29–7.34 (m, 1H, ArH), 7.35–7.43 (m, 4H, ArH), 7.54–7.60 (m, 2H, ArH).
13C-NMR (75 MHz, CDCl3): δ 28.2, 42.0, 58.5, 76.4, 78.1, 127.1, 128.4, 130.0, 133.3, 134.1, 134.9, 166.6,
176.4. Analysis calculated for C19H17N2O3Cl (356.81): C: 63.96, H: 4.80, N: 7.85; found C: 63.91, H: 4.65,
N: 7.92.
N-(3-Chlorobenzyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (19)
White solid, yield: 79.2%, (0.85 g); m.p. 137.3–138.8 ◦C; TLC: Rf = 0.7 (S1); UPLC (purity 99.5%):
tR = 5.87 min. LC–MS (ESI): m/z calculated for C19H17N2O3Cl (M + H)+ 357.09, found 357.1. 1H-NMR
(300 MHz, CDCl3): δ 2.76 (s, 4H, imide), 4.28–4.58 (m, 2H, CH2), 5.76 (s, 1H, CH), 5.99 (br. s, 1H,
NH), 7.12–7.18 (m, 1H, ArH), 7.20–7.28 (m, 3H, ArH), 7.35–7.41 (m, 3H, ArH), 7.55–7.61 (m, 2H, ArH).
13C-NMR (75 MHz, CDCl3): δ 28.2, 43.3, 58.5, 77.3–78.1, 125.5, 127.5 (d, J = 9.2 Hz), 129.3–130.4,
133.8–134.6, 139.7, 166.7, 176.4. Analysis calculated for C19H17N2O3Cl (356.81): C: 63.96, H: 4.80, N:
7.85; found C: 63.88, H: 4.62, N: 7.81.
N-(4-Chlorobenzyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (20)
White solid, yield: 75.7%, (0.81 g); m.p. 146.3–147.9 ◦C; TLC: Rf = 0.7 (S1); UPLC (purity 96.5%):
tR = 5.91 min. LC–MS (ESI): m/z calculated for C19H17N2O3Cl (M + H)+ 357.09, found 357. 1H-NMR
(300 MHz, CDCl3): δ 2.76 (s, 4H, imide), 4.30 (dd, J = 15.2, 5.4 Hz, 1H, CH2), 4.55 (dd, J = 15.2, 6.6 Hz,
1H, CH2), 5.75 (s, 1H, CH), 5.95 (br. s, 1H, NH), 7.16–7.22 (m, 2H, ArH), 7.25–7.30 (m, 2H, ArH),
7.34–7.40 (m, 3H, ArH), 7.54–7.59 (m, 2 H, ArH). 13C-NMR (75 MHz, CDCl3): δ 28.2, 43.2, 58.5, 77.3–78.1,
128.8 (d, J = 2.3 Hz), 129.2–130.0, 133.3, 134.1, 136.2, 166.6, 176.4. Analysis calculated for C19H17N2O3Cl
(356.81): C: 63.96, H: 4.80, N: 7.85; found C: 63.81, H: 4.92, N: 7.67.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(2-(trifluoromethyl)benzyl)acetamide (21)
White solid, yield: 67.1%, (0.78 g); m.p. 137.7–139.1 ◦C; TLC: Rf = 0.58 (S2); UPLC (purity 97%):
tR = 6.17 min. LC–MS (ESI): m/z calculated for C20H17N2O3F3 (M + H)+ 391.12, found 391.1. 1H-NMR
(300 MHz, CDCl3): δ 2.76 (s, 4H, imide) 4.60 (dd, J = 5.9 Hz, 1H, CH2) 4.66 (dd, J = 6.7 Hz, 1H, CH2)
5.74 (s, 1H, CH) 6.01 (br. s, 1H, NH) 7.33–7.42 (m, 4H, ArH) 7.51–7.63 (m, 5H, ArH). 13C-NMR (75 MHz,
CDCl3): δ 28.2, 40.7 (d, J = 2.3 Hz), 58.5, 124.2 (d, J = 249.9 Hz), 125.9 (d, J = 5.8 Hz), 126.1 (d, J = 5.8 Hz),
127.6, 129.4, 129.5, 129.8, 130.2, 132.4, 134.0, 166.8, 176.5. Analysis calculated for C20H17N2O3F3 (390.36):
C: 61.54, H: 4.39, N: 7.18; found C: 61.47, H: 4.21, N: 7.25.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethyl)benzyl)acetamide (22)
White solid, yield: 71.4%, (0.84); m.p. 152.8–153.4 ◦C; TLC: Rf = 0.54 (S2); UPLC (purity 98%):
tR = 6.19 min. LC–MS (ESI): m/z calculated for C20H17N2O3F3 (M + H)+ 391.12, found 391.0. 1H-NMR
(300 MHz, CDCl3): δ 2.78 (s, 4H, imide) 4.39 (dd, J = 15.4, 5.4 Hz, 1H, CH2) 4.65 (dd, J = 15.4,
6.7 Hz, 1H, CH2) 5.78 (s, 1H, CH) 6.02 (br. s, 1H, NH) 7.35–7.41 (m, 1H, ArH) 7.42–7.51 (m, 4H, ArH)
7.52–7.63 (m, 4H, ArH). 13C-NMR (75 MHz, CDCl3): δ 28.2, 43.4, 58.5, 124.0 (d, J = 272.9 Hz), 124.1 (q,
J = 3.8 Hz) 124.3 (q, J = 3.5 Hz), 129.4 (d, J = 27.6 Hz), 129.7 (d, J = 25.3 Hz), 132.4 (d, J = 249.9 Hz),
138.8, 166.9, 176.5. Analysis calculated for C20H17N2O3F3 (390.36): C: 61.54, H: 4.39, N:7.18; found C:
61.32, H: 4.48, N: 7.02.
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2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(4-(trifluoromethyl)benzyl)acetamide (23)
White solid, yield: 62.9%, (0.74 g); m.p. 174.5–176.0 ◦C; TLC: Rf = 0.86 (S2); UPLC (purity 98%):
tR = 6.25 min. LC–MS (ESI): m/z calculated for C20H17N2O3F3 (M + H)+ 391.12, found 391.1. 1H-NMR
(300 MHz, CDCl3): δ 2.77 (s, 4H, imide), 4.37 (dd, J = 15.6, 5.4 Hz, 1H, CH2), 4.66 (dd, J = 15.6, 6.8 Hz,
1H, CH2), 5.77 (s, 1H, CH) 6.03 (br. s, 1H, NH), 7.35–7.44 (m, 5H, ArH), 7.55–7.61 (m, 4H, ArH).
13C-NMR (75 MHz, CDCl3): δ 28.2, 43.4, 58.5, 124.1 (d, J = 271.8 Hz), 125.6 (d, J = 11.5 Hz), 125.6 (d,
J = 4.6 Hz), 127.6, 129.5, 129.8, 134.1, 141.8, 166.9,176.5. Analysis calculated for C20H17N2O3F3 (390.36):
C: 61.54, H: 4.39, N: 7.18; found C: 61.49, H: 4.21, N: 7.24.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethoxy)benzyl)acetamide (24)
White solid, yield: 67.4%, (0.82 g); m.p. 129.6–130.4 ◦C; TLC: Rf = 0.64 (S2); UPLC (purity >99.9%):
tR = 6.41 min. LC–MS (ESI): m/z calculated for C20H17F3N2O4 (M + H)+ 407.11, found 407.2. 1H-NMR
(500 MHz, CDCl3) δ 2.75 (s, 4H, imide), 4.34 (dd, J = 15.5, 5.7 Hz, 1H, CH2), 4.59 (dd, J = 15.5, 6.9 Hz,
1H, CH2), 5.75 (s, 1H, CH), 6.00 (br. s, 1H, NH), 7.07–7.11 (m, 2H, ArH), 7.20 (d, J = 8.0 Hz, 1H, ArH),
7.31–7.39 (m, 4H, ArH), 7.56–7.58 (m, 2H, ArH). 13C-NMR (126 MHz, CDCl3) δ 28.3, 43.4, 58.6, 120.5 (q,
J = 257.1 Hz), 119.9, 120.0, 125.8, 129.6, 129.6, 129.9, 130.2, 134.2, 140.2, 149.5, 166.9, 176.6. Analysis
calculated for C20H17F3N2O4 (406.36): C: 59.11, H: 4.22, N: 6.89; found C: 59.19, H: 4.38, N: 6.95.
2-(2,5-Dioxopyrrolidin-1-yl)-N-phenethyl-2-phenylacetamide (25)
White solid, yield: 73.5% (0.74 g); m.p. 138.4–139.2 ◦C; TLC: Rf = 0.4 (S2); UPLC (purity 99.0%):
tR = 5.57 min. LC–MS (ESI): m/z calculated for C20H20N2O3 (M + H)+ 337.15, found 337.2. 1H-NMR
(500 MHz, CDCl3) δ 2.73 (s, 4H, imide), 2.76 (t, J = 6.8 Hz, 2H, CH2), 3.34–3.41 (m, 1H, CH2), 3.60
(dd, J = 13.4, 6.6 Hz, 1H, CH2), 5.59 (br. s, 1H, NH), 5.63 (s, 1H, CH), 7.07–7.10 (m, 2H, ArH),
7.15–7.20 (m, 1H, ArH), 7.20–7.29 (m, 3H, ArH), 7.30–7.33 (m, 2H, ArH), 7.44 (d, J = 6.7 Hz, 2H, ArH).
13C-NMR (126 MHz, CDCl3) δ 28.3, 35.3, 41.4, 58.7, 126.6, 128.6, 128.7, 128.8, 128.9, 129.4, 129.8, 134.3,
138.6, 166.6, 176.6. Analysis calculated for C20H20N2O3 (336.39): C: 71.41, H: 5.99, N: 8.33; found C:
71.29, H: 5.87, N: 8.49.
2-(2,5-Dioxopyrrolidin-1-yl)-N-(2-fluorophenethyl)-2-phenylacetamide (26)
White solid, yield: 69.8% (0.73 g); m.p. 142.4–142.8 ◦C; TLC: Rf = 0.44 (S2); UPLC (purity >99.9%):
tR = 5.66 min. LC–MS (ESI): m/z calculated for C20H19FN2O3 (M + H)+ 355.14, found 355.2. 1H-NMR
(500 MHz, CDCl3) δ 2.74 (s, 4H, imide), 2.77–2.81 (m, 1H, CH2), 2.82–2.87 (m, 1H, CH2), 3.42 (dd,
J = 13.7, 6.8 Hz, 1H, CH2), 3.56 (dd, J = 13.4, 6.5 Hz, 1H, CH2), 5.63 (s, 2H, NH, CH), 6.95 (t, J = 8.8
Hz, 1H, ArH), 7.02 (t, J = 7.3 Hz, 1H, ArH), 7.13–7.18 (m, 2H, ArH), 7.30–7.34 (m, 3H, ArH), 7.46 (d,
J = 6.2 Hz, 2H, ArH). 13C-NMR (126 MHz, CDCl3) δ 28.3, 28.9, 40.2, 58.7, 115.4 (d, J = 22.3 Hz), 124.2 (d,
J = 3.6 Hz), 125.5 (d, J = 15.7 Hz), 128.4 (d, J = 8.4 Hz), 129.4, 129.4, 129.9, 131.4 (d, J = 4.8 Hz), 134.2,
161.2 (d, J = 245.1 Hz), 166.7, 176.6. Analysis calculated for C20H19FN2O3 (354.38): C: 67.79, H: 5.40,
N: 7.91; found C: 67.61, H: 5.51, N: 7.84.
N-(3-Chlorophenethyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (27)
White solid, yield: 73.4% (0.82 g); mp. 137.4–138.2 ◦C; TLC: Rf = 0.62 (S2); UPLC (purity >99.9%):
tR = 6.20 min. LC–MS (ESI): m/z calculated for C20H19ClN2O3 (M + H)+ 371.11, found 371.4. 1H-NMR
(500 MHz, CDCl3) δ 2.73–2.77 (m, 6H, imide, CH2), 3.29 (td, J = 13.3, 6.6 Hz, 1H, CH2), 3.63 (dd, J = 13.5,
6.6 Hz, 1H, CH2), 5.57 (t, J = 5.2 Hz, 1H, NH), 5.63 (s, 1H, CH), 6.99–7.01 (m, 1H, ArH), 7.14–7.17
(m, 3H, ArH), 7.32–7.34 (m, 3H, ArH), 7.44–7.47 (m, 2H, ArH). 13C-NMR (126 MHz, CDCl3) δ 28.3,
35.1, 41.2, 58.7, 126.8, 127.1, 129.2, 129.4, 129.5, 129.7, 129.9, 134.2, 134.4, 140.8, 166.7, 176.6. Analysis
calculated for C20H19ClN2O3 (370.83): C: 64.78, H: 5.16, N: 7.55; found C: 64.99, H: 5.05, N: 7.81.
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N-(4-Chlorophenethyl)-2-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide (28)
White solid, yield: 68.6% (0.76 g); m.p. 137.2–137.8 ◦C; TLC: Rf = 0.52 (S2); UPLC (purity >99.9%):
tR = 6.10 min. LC–MS (ESI): m/z calculated for C20H19ClN2O3 (M + H)+ 371.11, found 371.4. 1H-NMR
(500 MHz, CDCl3) δ 2.72–2.76 (m, 6H, imide, CH2), 3.31 (dd, J = 13.2, 5.7 Hz, 1H, CH2), 3.59 (dd,
J = 13.2, 6.3 Hz, 1H, CH2), 5.56 (t, J = 5.2 Hz, 1H, NH), 5.62 (s, 1H, CH), 7.02–7.05 (m, 2H, Ar), 7.18–7.20
(m, 2H, ArH), 7.29–7.35 (m, 3H, ArH), 7.42 (d, J = 6.8 Hz, 2H, ArH). 13C-NMR (126 MHz, CDCl3) δ
28.3, 34.7, 41.2, 58.7, 128.8, 129.4, 129.4, 129.8, 130.2, 132.4, 134.2, 137.1, 166.6, 176.6. Analysis calculated
for C20H19ClN2O3 (370.83): C: 64.78, H: 5.16, N: 7.55; found C: 64.53, H: 5.39, N: 7.72.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethyl)phenethyl)acetamide (29)
White solid, yield: 69.3% (0.80 g); m.p. 149.2–150.4 ◦C; TLC: Rf = 0.58 (S2); UPLC (purity >99.9%):
tR = 6.92 min. LC–MS (ESI): m/z calculated for C21H19F3N2O3 (M + H)+ 405.14, found 405.3. 1H-NMR
(500 MHz, CDCl3) δ 2.75 (s, 4 H, imide) 2.81–2.89 (m, 2 H, CH2) 3.29–3.38 (m, 1 H, CH2) 3.66 (dd, J = 13.5,
6.6 Hz, 1 H, CH2) 5.59 (br. s, 1 H, NH) 5.63 (s, 1 H, CH) 7.28–7.33 (m, 3 H, ArH) 7.33–7.39 (m, 2 H, ArH)
7.41–7.47 (m, 4 H, ArH). 13C-NMR (126 MHz, CDCl3) δ 28.3, 35.2, 41.3, 58.7, 124.15 (q, J = 272.2 Hz),
123.5 (q, J = 3.6 Hz), 125.7 (q, J = 3.6 Hz), 129.1, 129.4, 129.5, 129.7, 130.1 (q, J = 32.0 Hz), 132.4, 134.2,
139.8, 166.8 176.6. Analysis calculated for C21H19F3N2O3 (404.39): C: 62.37, H: 4.74, N: 6.93, found C:
62.22, H: 4.66, N: 7.02.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-(trifluoromethoxy)phenethyl)acetamide (30)
White solid, yield: 64.3% (0.81 g); m.p. 113.3–114.2 ◦C; TLC: Rf = 0.62 (S2); UPLC (purity >99.9%):
tR = 6.64 min. LC–MS (ESI): m/z calculated for C21H19F3N2O4 (M + H)+ 421.13, found 421.1. 1H-NMR
(500 MHz, CDCl3) δ 2.75 (s, 4H), 2.80 (t, J = 6.9 Hz, 2H, CH2), 3.30–3.38 (m, 1H, CH2), 3.63 (dd, J = 13.5,
6.6 Hz, 1H, CH2), 5.59 (t, J = 5.4 Hz, 1H, NH), 5.64 (s, 1H, CH), 6.99 (s, 1H, ArH), 7.03–7.07 (m, 2H, ArH),
7.25–7.34 (m, 4H, ArH), 7.45 (d, J = 6.6 Hz, 2H, ArH). 13C-NMR (126 MHz, CDCl3) δ 28.3, 35.1, 41.2,
58.7, 120.2 (d, J = 309.6 Hz), 120.5 (d, J = 256.5 Hz), 127.3, 129.4, 129.7 (t, J = 31.1 Hz), 134.2, 141.1, 149.5,
166.7, 176.6. Analysis calculated for C21H19F3N2O4 (420.39): C: 60.00, H: 4.56, N: 6.66; found C: 60.21,
H: 4.42, N: 6.48.
2-(2,5-Dioxopyrrolidin-1-yl)-2-phenyl-N-(3-phenylpropyl)acetamide (31)
White solid, yield: 73.7% (0.77 g); m.p. 133.1–133.9 ◦C; TLC: Rf = 0.50 (S2); UPLC (purity >99.9%):
tR = 6.16 min. LC–MS (ESI): m/z calculated for C21H22N2O3 (M + H)+ 351.16, found 351.2. 1H-NMR
(500 MHz, CDCl3) δ 1.78 (td, J = 7.5, 2.9 Hz, 2H, CH2), 2.58 (t, J = 7.7 Hz, 2H, CH2), 2.74 (s, 4H,
imide), 3.18–3.22 (m, 1H, CH2), 3.31–3.36 (m, 1H, CH2), 5.55–5.63 (m, 1H, CH2), 5.66 (s, 1H, NH),
7.09–7.17 (m, 3H, ArH), 7.22–7.24 (m, 2H, ArH), 7.38–7.40 (m, 3H, ArH), 7.53–7.55 (m, 2H, ArH).
13C-NMR (126 MHz, CDCl3) δ 28.3, 31.0, 33.1, 39.7, 58.7, 126.1, 128.4, 128.5, 129.5, 129.9, 134.5, 141.3,
166.6, 176.6. Analysis calculated for C21H22N2O3 (350.42): C: 71.98, H: 6.33, N: 7.99; found C: 71.62,
H: 6.28, N: 8.12.
3.2. Anticonvulsant Activity
Experiments were performed on adult male CD-1 mice weighing 22–26 g, purchased from
the Animal House at the Faculty of Pharmacy, Jagiellonian University Medical College, Cracow,
Poland. The animals were kept at room temperature of 20 ± 2 ◦C under standard conditions. Initial
qualitative efficacy screening was conducted in groups of four mice. To obtain the ED50 (median
effective dose), at least three groups of six mice were injected with various doses of tested compounds.
The anticonvulsant activity studies were approved by the Local Ethical Committee in Cracow, Poland
(No 111/2016, 165/2018, 228A/2019, 360/2019) and conducted in compliance with the European Union
Directive of 22 September 2010 (2010/63/EU). The tested substances were suspended in a 1% solution of
Tween-80 and administered via the intraperitoneal (i.p.) route in a volume of 10 mL/kg body weight.
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LTG, and VPA were purchased in Sigma-Aldrich (St. Louis, MO, USA), LCS in UCB Pharma
(Braine-l’Alleud, Belgium). The pretreatment times for the aforementioned reference AEDs were based
on information from the National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy
Therapy Screening Program (ETSP) [38]. The in vivo procedures for the following tests are reported
elsewhere: maximal electroshock seizure test (MES) [14], the 6 Hz (32 mA) seizure model [14], and the
rotarod test for acute neurological toxicity [9].
3.3. Antinociceptive Activity
The experimental groups consisted of 6–12 adult male Albino Swiss mice (CD-1, 18–25 g).
Each animal was tested only once. Immediately after the assay, the animals were sacrificed by cervical
dislocation. Behavioral measurements were observed by trained observers. The in vivo antinociceptive
assays were in accordance with Polish regulations and European Union Directive of 22 September 2010
(2010/63/EU). All procedures were carried out according to the rules of the International Council on
Laboratory Animal Science (ICLAS) and were approved by the Local Ethical Committee in Cracow,
Poland (approval No 104/2015, 111/2016, and 179/2017). The tested substances were suspended in 1%
aqueous solution of Tween-80 and were injected i.p. 30 min prior to the test. Control group animals
(negative control) were administered with an appropriate amount of vehicle (Tween-80, 1% aqueous
solution, i.p.) 30 min prior to the test.
The experimental in vivo procedures were previously reported for the formalin test [39];
compounds 4 and 30 were tested in three doses—40, 80, 120 mg/kg (4), and 20, 40, 80 mg/kg (30).
Before formalin application, different groups of animals were injected i.p. with vehicle (10 mL/kg,
negative control). The in vivo procedure for the model of capsaicin-induced nociception was
previously reported [40]; the animals were pretreated with vehicle (10 mL/kg, negative control)
and the dose–response of investigated compounds was evaluated at 40, 80, 120 mg/kg (4), and 20,
40, 80 mg/kg (30). The in vivo procedure for the model of OXPT-induced peripheral neuropathy was
previously reported [41]; the mice with developed tactile allodynia were pretreated i.p. with test
compound 30 (20, 40, and 80 mg/kg) and vehicle.
3.4. In Vivo Data Analysis
3.4.1. Anticonvulsant Activity and Neurotoxicity Studies
The probit analysis [23] was used to calculate the ED50 and TD50 values with 95% confidence limits.
The PI values (protective indexes) for the tested substance and standard AEDs were calculated by
dividing the TD50 value, as determined in the rotarod test, by the respective ED50 value, as determined
in the MES or 6 Hz (32 mA) tests.
3.4.2. Antinociceptive Activity Studies
Data are presented as means ± standard error of the mean (SEM). The GraphPad Prism Software
(v.5) was used to analyze the vast majority of data. Statistically significant differences between groups
were calculated using one-way analysis of variance (ANOVA) and the post hoc Dunnett’s multiple
comparison test or two-way analysis of variance (ANOVA). The criterion for significance was set
at p < 0.05. The log-probit method was applied to statistically determine the ED50 values with 95%
confidence limits.
3.5. In Vitro ADME-Tox Studies
3.5.1. Permeability
Precoated PAMPA Plate System Gentest™ was provided by Corning, (Tewksbury, MA, USA).
The detailed procedure and proper formulas were described previously [36].
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3.5.2. Metabolic Stability
These assays were performed on human liver microsomes (HLMs), purchased from Sigma-Aldrich
(St. Louis, MO, USA), according to [14].
3.5.3. Influence on Recombinant Human CYP3A4, CYP2D6, and CYP2C9 Cytochrome P450 Isoforms
The luminescent CYP3A4 P450-Glo™, CYP2D6 P450-Glo™, and CYP2C9 P450-Glo™ assays and
protocols were provided by Promega (Madison, WI, USA) [42]. The detailed procedures are reported
in the literature (CYP3A4 [14,15], CYP2D6 [15], and CYP2C9 [36]).
3.5.4. Hepatotoxicity Assessment
These studies were performed on hepatoma HepG2 cells, according to a protocol reported
previously [43]
3.6. In Silico Studies
The biotransformation pathways for metabolites 2, 24, and 30 were estimated in silico by MetaSite
6.0.1 provided by Molecular Discovery Ltd. (Hertfordshire, UK). The metabolic pathways and probable
metabolite structures were studied using a liver computational model [44].
3.7. In Vitro Binding and Functional Assays
Binding studies were carried out commercially in Eurofines Laboratories (Poitiers, France).
The functional assays were performed in Eurofins Panlabs Discovery Services Taiwan, Ltd.
(New Taipei City, Taiwan). All procedures are described elsewhere (for details, see Table S4 in
Supplementary Materials).
4. Conclusions
In the current studies, we developed a new series of hybrid anticonvulsants with an incorporated
phenylglycine moiety. These compounds were designed as analogues or previously reported alanine
derivatives which showed broad-spectrum and potent anticonvulsant efficacy. As a result, several
compounds described herein revealed potent protection in the maximal electroshock (MES) test and
the psychomotor 6 Hz (32 mA) seizure model in mice, which are recognized as the standard and widely
applied seizure models for early identification of new AED candidates. The most potent anticonvulsant
activity and satisfactory safety profile were demonstrated for compound 30. In addition, 30 was effective
in the formalin test of tonic pain, the capsaicin-induced pain model, and the oxaliplatin-induced
neuropathic pain model in mice. The plausible mechanism of action of 30 is probably related to
the inhibition of calcium currents mediated by Cav1.2 (L-type) channels. Notably, 30 revealed high
metabolic stability on human liver microsomes, negligible hepatotoxicity, and relatively weak inhibition
of cytochrome P450 isoenzymes. In conclusion, compound 30 seems to be worthy of further and more
detailed characterization as a potential candidate for the treatment of epilepsy and neuropathic pain.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/22/
8780/s1. General procedure for the preparation staring amine derivatives (A1 and A2); Table S1. Anticonvulsant
activity and acute neurotoxicity screening data in the MES, 6 Hz (32 mA), and rotarod tests in mice i.p. (dose
of 100 mg/kg)—compounds 3–13; Table S2. Anticonvulsant activity and acute neurotoxicity screening data
in the MES, 6 Hz (32 mA), and rotarod tests in mice i.p. (dose of 100 mg/kg)—compounds 14–24; Table S3.
Anticonvulsant activity and acute neurotoxicity screening data in the MES, 6 Hz (32 mA), and rotarod tests in
mice i.p. (dose of 100 mg/kg)—compounds 25–31; Table S4. In vitro binding and functional assays; Figure S1.
UPLC chromatogram after 120 min incubation of compound 4 with HLMs; Figure S2. MS ion fragment analyses
and most probable structures of compound 4 metabolites M1–M3; Figure S3. UPLC chromatogram after 120 min
incubation of compound 24 with HLMs; Figure S4. MS ion fragment analyses and most probable structure of 24
metabolite M1; Figure S5. UPLC chromatogram after 120 min incubation of compound 30 with HLMs; Figure S6.
MS ion fragment analyses and most probable structures of 30 metabolites M1 and M2; Figure S7. The MetaSite
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6.0.1. software predictions of the most probably sites of compounds 4, 24, and 30 metabolism; 1H-NMR and
13C-NMR spectra for selected final compounds.
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HLMs Human liver microsomes
HMDS Hexamethyldisilazane
6 Hz 6 Hz seizure test
KE Ketoconazole
LCS Lacosamide
LiAlH4 Lithium aluminum hydride
LTG Lamotrigine
Lacosamide Acetonitrile




PAMPA Parallel artificial membrane permeability assay




TPE Time of peak effect
VPA Valproic acid
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